A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis
Liver International · 2025
DOI: 10.1111/liv.70406 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Liver International, 2025. Verfasst von Javier Armisen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Hauptthemen laut MEDLINE: Peroxidase, Non-alcoholic Fatty Liver Disease, Fatty Liver. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background and Aims Neutrophil myeloperoxidase is involved in different inflammatory diseases, including metabolic dysfunction‐associated steatohepatitis (MASH). Mitiperstat is a highly potent myeloperoxidase inhibitor. This phase 2a clinical trial evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of mitiperstat in patients with non‐cirrhotic MASH.
Methods
The study enrolled 112 adult participants with histological MASH F1–3 fibrosis and increased alanine aminotransferase (ALT) levels. Participants were randomised 1:1 to once‐daily mitiperstat 5 mg or placebo. Primary and secondary endpoints were absolute and placebo‐adjusted changes from baseline to week 12 in ALT and N‐terminal type‐III collagen propeptide (Pro‐C3) levels. Exploratory endpoints included other MASH‐related biomarkers.
Results
At week 12, there were no significant changes versus placebo for ALT (+7.5%, p = 0.893) and Pro‐C3 (−0.9%, p = 0.396), or any other MASH‐related biomarkers. Mitiperstat was safe and well tolerated.
Conclusion
This study does not provide proof of concept that mitiperstat 5 mg exerts an anti‐inflammatory/anti‐fibrotic effect in MASH. Trial Registration ClincalTrials.gov identifier: NCT05638737
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
- Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
- Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Global Patient Safety, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
ORCID-Profile: Armando Flor, Mikael Sunnåker
Förderung
- AstraZeneca
Zitieren
APA
Armisen, J., Flor, A., Eriksson, J., Nelander, K., Bhattacharya, C. S., Sunnåker, M., Carter, D., Trebski, M., Gårdmark, E., Aurell, M., Whatling, C., Challis, B., Vespasiani-Gentilucci, U., & COSMOS Investigators (2025). A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. https://doi.org/10.1111/liv.70406
Vancouver
Armisen J, Flor A, Eriksson J, Nelander K, Bhattacharya CS, Sunnåker M, et al. A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. 2025. doi:10.1111/liv.70406
BibTeX
@article{Armisen2025,
author = {Armisen, Javier and Flor, Armando and Eriksson, John and Nelander, Karin and Bhattacharya, Chandrali S and Sunnåker, Mikael and Carter, Debra and Trebski, Monika and Gårdmark, Emma and Aurell, Malin and Whatling, Carl and Challis, Benjamin and Vespasiani-Gentilucci, Umberto and COSMOS Investigators, COSMOS Investigators},
title = {A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70406}
}
EUVIMED